Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -124.85% | -262.22% | -515.75% | -1,149.62% | 1,083.75% |
| Total Depreciation and Amortization | -21.00% | -26.65% | -23.41% | 8,057.14% | 19.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -30.73% | -- |
| Total Other Non-Cash Items | 116.29% | 280.65% | 70.64% | 2,793.09% | -240.48% |
| Change in Net Operating Assets | -42.87% | -26.25% | -116.57% | 47.02% | 2,481.02% |
| Cash from Operations | 16.82% | -84.78% | -97.92% | -28.55% | -13.01% |
| Capital Expenditure | -91.49% | -102.24% | 99.01% | 38.46% | 43.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -661.18% | -263.04% | -- | -128.70% | 83.93% |
| Cash from Investing | 89.47% | -203.62% | 78.84% | -93.94% | -1,044.12% |
| Total Debt Issued | -- | -- | -- | 15.38% | -- |
| Total Debt Repaid | -19.31% | -22.49% | -13.71% | -213.96% | -97.82% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -15.96% | 140.23% | -11.63% | -123.51% | -97.38% |
| Foreign Exchange rate Adjustments | -102.77% | 140.31% | -83.51% | -51.64% | -60.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 101.59% | 163.71% | -243.88% | -349.49% | -271.01% |